JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis

被引：57
作者：
Regina, S.
Herault, O.
D'Alteroche, L.
Binet, C.
Gruel, Y.
机构：
[1] Trousseau Hosp, Dept Haematol Haemostasis, Tours, France
[2] Trousseau Hosp, INSERM, U618, Tours, France
[3] Univ Tours, Tours, France
[4] Bretonneau Hosp, Haematol Lab, Tours, France
[5] Bretonneau Hosp, INSERM, ESPRI EA3855, Tours, France
[6] Trousseau Hosp, Dept Gastroenterol & Hepatol, Tours, France
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1111/j.1538-7836.2007.02384.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：859 / 861
页数：3
相关论文
共 17 条
  • [1] Arellano-Rodrigo E, 2006, HAEMATOL-HEMATOL J, V91, P169
  • [2] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
    Baxter, EJ
    Scott, LM
    Campbell, PJ
    East, C
    Fourouclas, N
    Swanton, S
    Vassiliou, GS
    Bench, AJ
    Boyd, EM
    Curtin, N
    Scott, MA
    Erber, WN
    Green, AR
    [J]. LANCET, 2005, 365 (9464) : 1054 - 1061
  • [3] PORTAL-VEIN THROMBOSIS - A REVIEW
    COHEN, J
    EDELMAN, RR
    CHOPRA, S
    [J]. AMERICAN JOURNAL OF MEDICINE, 1992, 92 (02) : 173 - 182
  • [4] The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis
    Colaizzo, D.
    Amitrano, L.
    Tiscia, G. L.
    Scenna, G.
    Grandone, E.
    Guardascione, M. A.
    Brancaccio, V.
    Margaglione, M.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (01) : 55 - 61
  • [5] Cause of portal or hepatic venous thrombosis in adults:: The role of multiple concurrent factors
    Denninger, MH
    Chaït, Y
    Casadevall, N
    Hillaire, S
    Guillin, MC
    Bezeaud, A
    Erlinger, S
    Briere, J
    Valla, D
    [J]. HEPATOLOGY, 2000, 31 (03) : 587 - 591
  • [6] A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
    James, C
    Ugo, V
    Le Couédic, JP
    Staerk, J
    Delhommeau, F
    Lacout, C
    Garçon, L
    Raslova, H
    Berger, R
    Bennaceur-Griscelli, A
    Villeval, JL
    Constantinescu, SN
    Casadevall, N
    Vainchenker, W
    [J]. NATURE, 2005, 434 (7037) : 1144 - 1148
  • [7] JAK2 mutation: The best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis?
    Janssen, Harry L. A.
    Leebeek, Frank W. G.
    [J]. HEPATOLOGY, 2006, 44 (06) : 1391 - 1393
  • [8] A gain-of-function mutation of JAK2 in myeloproliferative disorders
    Kralovics, R
    Passamonti, F
    Buser, AS
    Teo, S
    Tiedt, R
    Passweg, JR
    Tichelli, A
    Cazzola, M
    Skoda, RC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) : 1779 - 1790
  • [9] Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
    Levine, RL
    Wadleigh, M
    Cools, J
    Ebert, BL
    Wernig, G
    Huntly, BJP
    Boggon, TJ
    Wlodarska, L
    Clark, JJ
    Moore, S
    Adelsperger, J
    Koo, S
    Lee, JC
    Gabriel, S
    Mercher, T
    D'Andrea, A
    Fröhling, S
    Döhner, K
    Marynen, P
    Vandenberghe, P
    Mesa, RA
    Tefferi, A
    Griffin, JD
    Eck, MJ
    Sellers, WR
    Meyerson, M
    Golub, TR
    Lee, SJ
    Gilliland, DG
    [J]. CANCER CELL, 2005, 7 (04) : 387 - 397
  • [10] The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera
    Lippert, Eric
    Boissinot, Marjorie
    Kralovics, Robert
    Girodon, Francois
    Dobo, Irene
    Praloran, Vincent
    Boiret-Dupre, Nathalie
    Skoda, Radek C.
    Hermouet, Sylvie
    [J]. BLOOD, 2006, 108 (06) : 1865 - 1867
12